New promising β-lactamase inhibitors for clinical use

Extended-spectrum beta-lactamase-producing bacteria are not detected in supragingival plaque samples from human fecal carriers of ESBL-producingEnterobacteriaceae

(2014) Arne Søraas et al.   Journal of Oral Microbiology

In VitroActivity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

(2013) Sarah M. Drawz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds

(2013) Ellie J.C. Goldstein et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

(2013) George G. Zhanel et al.   DRUGS

β-Lactamase inhibitors: a review of the patent literature (2010 – 2013)

(2013) John D Buynak   EXPERT OPINION ON THERAPEUTIC PATENTS

Activity of biapenem (RPX2003) combined with the boronate  -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

(2013) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

β-Lactamase Inhibitors: An Update

(2013) Jiao Chen et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance

(2013) Richard R. Watkins et al.   Frontiers in Microbiology

Metallo-β-lactamase structure and function

(2012) Timothy Palzkill   Annals of the New York Academy of Sciences

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current Trends in β-Lactam Based β-Lactamases Inhibitors

(2011) S. Biondi et al.   CURRENT MEDICINAL CHEMISTRY

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Updated Functional Classification of  -Lactamases

(2009) K. Bush et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem

(2009) Timothy A. Blizzard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors

(2007) Stefania Morandi et al.   BIOORGANIC & MEDICINAL CHEMISTRY